R&G PharmaStudies Co., Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

R&G PharmaStudies Co., Ltd.

Why is R&G PharmaStudies Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 8.48% and Operating profit at 4.91% over the last 5 years

Flat results in Sep 25

OPERATING CASH FLOW(Y) Lowest at CNY 106.21 MM
DEBT-EQUITY RATIO (HY) Highest at -87.14 %
RAW MATERIAL COST(Y) Grown by 11.76% (YoY)

With ROE of 7.16%, it has a attractive valuation with a 1.62 Price to Book Value

Over the past year, while the stock has generated a return of 16.79%, its profits have risen by 6.3%
At the current price, the company has a high dividend yield of 0.3

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to R&G PharmaStudies Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is R&G PharmaStudies Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

R&G PharmaStudies Co., Ltd.

16.79%

0.92

61.25%

China Shanghai Composite

16.01%

1.07

14.97%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

8.48%

EBIT Growth (5y)

4.91%

EBIT to Interest (avg)

71.87

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.90

Sales to Capital Employed (avg)

0.40

Tax Ratio

9.65%

Dividend Payout Ratio

10.88%

Pledged Shares

Institutional Holding

ROCE (avg)

2,584.81%

ROE (avg)

2,376.51%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.62

EV to EBIT

10.93

EV to EBITDA

8.41

EV to Capital Employed

7.64

EV to Sales

1.83

PEG Ratio

Dividend Yield

0.30%

ROCE (Latest)

69.92%

ROE (Latest)

7.16%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

Bullish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

NET SALES(Q)

Highest at CNY 227.71 MM

PRE-TAX PROFIT(Q)

At CNY 37.08 MM has Grown at 53.42%

-7What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at CNY 106.21 MM

DEBT-EQUITY RATIO (HY)

Highest at -87.14 %

RAW MATERIAL COST(Y)

Grown by 11.76% (YoY

OPERATING PROFIT MARGIN(Q)

Lowest at 14.79 %

Here's what is working for R&G PharmaStudies Co., Ltd.

Net Sales

Highest at CNY 227.71 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Net Sales

At CNY 227.71 MM has Grown at 24.48%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Pre-Tax Profit

At CNY 37.08 MM has Grown at 53.42%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Here's what is not working for R&G PharmaStudies Co., Ltd.

Operating Cash Flow

Lowest at CNY 106.21 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Debt-Equity Ratio

Highest at -87.14 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Operating Profit Margin

Lowest at 14.79 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Raw Material Cost

Grown by 11.76% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales